ubiquinone has been researched along with Headache* in 6 studies
1 review(s) available for ubiquinone and Headache
Article | Year |
---|---|
Complementary and alternative treatments for childhood headaches.
Parents frequently ask health care professionals to provide "natural" migraine care for their children and often use herbs, minerals, vitamins, and supplements to treat their children's migraines, thinking that these over-the-counter alternatives are less toxic than prescription medications. The only randomized controlled trial on any alternative treatment for pediatric migraine is for magnesium, and the results were equivocal. Results of two other uncontrolled trials of magnesium, one for migraine and one for episodic tension-type headache, were positive. There is one positive uncontrolled trial each for coenzyme Q10 and Petasites for prevention of pediatric migraine. There are no trials to indicate the safety or efficacy of riboflavin or feverfew for pediatric headache. Topics: Child; Complementary Therapies; Headache; Humans; Magnesium; Riboflavin; Ubiquinone | 2008 |
2 trial(s) available for ubiquinone and Headache
Article | Year |
---|---|
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.
To determine if future studies of coenzyme Q(10) and GPI-1485 in Parkinson disease (PD) may be warranted.. We conducted a randomized, double-blind, calibrated futility clinical trial of coenzyme Q10 and GPI-1485 in early untreated PD using placebo data from the DATATOP study to establish the futility threshold.. The primary outcome measure (change in total Unified Parkinson's Disease Rating Scale scores over 1 year) did not meet the prespecified criteria for futility for either agent. Secondary analyses using calibration controls and other more recent placebo data question the appropriateness of the predetermined definition of futility, and suggest that a more restrictive threshold may be needed.. Coenzyme Q(10) and GPI-1485 may warrant further study in Parkinson disease, although the data are inconsistent. Additional factors (cost, availability of other agents, more recent data on placebo outcomes, other ongoing trials) should also be considered in the selection of agents for Phase III studies. Topics: Aged; Coenzymes; Double-Blind Method; Female; Headache; Humans; Male; Middle Aged; Nausea; Parkinson Disease; Tacrolimus; Ubiquinone | 2007 |
A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone).
Topics: Administration, Oral; Adult; Area Under Curve; Back Pain; Biological Availability; Capsules; Coenzymes; Cross-Over Studies; Double-Blind Method; Female; Gelatin; Headache; Humans; Male; Pruritus; Sex Factors; Sinusitis; Time Factors; Ubiquinone; Vitamins | 2007 |
3 other study(ies) available for ubiquinone and Headache
Article | Year |
---|---|
The use of nutraceutics in children's and adolescent's headache.
Nutraceutics are the most used non-pharmacological remedies for migraine's prophylaxis in children and adolescents. Doctors interested in use of nutraceuticals for a complete treatment of children's headache should be adequately informed on this treatments' efficacy and safety. Actually there is a lack of official guidelines about use of nutraceuticals in migraine's prevention in children and adolescent and there are few studies with limited efficacy evidences. The most used nutraceuticals for adolescent's and children's headache prophylaxis are: magnesium, coenzyme Q10, riboflavin, butterbur, feverfew and melatonin. Further Randomised Controlled Trials are needed for a better effectiveness evaluation in nutraceuticals' use for migraine treatment in child and adolescent. Topics: Adolescent; Child; Dietary Supplements; Headache; Humans; Magnesium; Migraine Disorders; Petasites; Tanacetum parthenium; Treatment Outcome; Ubiquinone | 2017 |
Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q₁₀ effect on clinical improvement.
Fibromyalgia (FM) is a chronic pain syndrome with unknown etiology and a wide spectrum of symptoms such as allodynia, debilitating fatigue, joint stiffness and migraine. Recent studies have shown some evidences demonstrating that oxidative stress is associated to clinical symptoms in FM of fibromyalgia. We examined oxidative stress and bioenergetic status in blood mononuclear cells (BMCs) and its association to headache symptoms in FM patients. The effects of oral coenzyme Q(10) (CoQ(10)) supplementation on biochemical markers and clinical improvement were also evaluated.. We studied 20 FM patients and 15 healthy controls. Clinical parameters were evaluated using the Fibromyalgia Impact Questionnaire (FIQ), visual analogues scales (VAS), and the Headache Impact Test (HIT-6). Oxidative stress was determined by measuring CoQ(10), catalase and lipid peroxidation (LPO) levels in BMCs. Bioenergetic status was assessed by measuring ATP levels in BMCs.. We found decreased CoQ(10), catalase and ATP levels in BMCs from FM patients as compared to normal control (P < 0.05 and P < 0.001, respectively) We also found increased level of LPO in BMCs from FM patients as compared to normal control (P < 0.001). Significant negative correlations between CoQ(10) or catalase levels in BMCs and headache parameters were observed (r = -0.59, P < 0.05; r = -0.68, P < 0.05, respectively). Furthermore, LPO levels showed a significant positive correlation with HIT-6 (r = 0.33, P<0.05). Oral CoQ(10) supplementation restored biochemical parameters and induced a significant improvement in clinical and headache symptoms (P < 0.001).. The results of this study suggest a role for mitochondrial dysfunction and oxidative stress in the headache symptoms associated with FM. CoQ10 supplementation should be examined in a larger placebo controlled trial as a possible treatment in FM. Topics: Adenosine Triphosphate; Adult; Catalase; Female; Fibromyalgia; Headache; Humans; Lipid Peroxidation; Middle Aged; Oxidative Stress; Pain Measurement; Ubiquinone; Vitamins | 2012 |
Highlights of the 11th Congress of the International Headache Society, held September 13-16, 2003, in Rome, Italy. Updating the headache classification system.
The International Headache Society held their 11th biennial congress in Rome, Italy, on September 13-16, 2003. The meeting featured the introduction of the second edition to the International Classification of Headache Disorders, the first update to the document since its presentation in 1988. This report discusses some of the different classifications of headache and their treatments as discussed at the congress. Topics: Anti-Inflammatory Agents, Non-Steroidal; Botulinum Toxins, Type A; Clinical Trials as Topic; Female; Headache; Humans; Mutation; Piperazines; Pregnancy; Quinazolines; Serotonin Receptor Agonists; Ubiquinone | 2003 |